|

Involving Patients in Mesothelioma Research

Involving Patients in Mesothelioma Research

Involving patients and the public in mesothelioma research can help scientists to make meaningful breakthroughs.

A group of researchers from the United Kingdom spoke with twenty-three mesothelioma researchers. They wanted to get their opinions on how helpful it would be to involve patients and the public in their mesothelioma research.

The researchers also ran online workshops and interviews to get the thoughts of patients and members of the public.

Doing Meaningful Mesothelioma Research

Mesothelioma is a rare form of cancer caused by asbestos exposure. It develops on the lining of internal organs like the lungs or abdominal cavity. There are about 2,000 cases of mesothelioma diagnosed in the United States each year.

Doing research on mesothelioma and effective treatments can be hard for a few reasons. It is hard to study because mesothelioma symptoms usually appear late in the disease. Patients typically survive between only 8 and 14 months after diagnosis.

The experience of living with a mesothelioma diagnosis is mentally and emotionally challenging for patients and their families. These factors can make researchers unwilling to approach people affected by mesothelioma to participate in research.

But there are studies that show that when patients get involved in research, they can feel more positive and hopeful about their condition.

Involving Patients and the Public in Research

The patients and members of the public said that participating in research would give them a sense of meaning and hope for the future. It would also help to create a community and reduce feelings of loneliness.

One participant said, “If you get to either talk to these people on different studies or see a paper, at least it gives you a bit of positivity.”

Many patients and members of the public were confused about how to get involved in research. They also did not understand what would happen if they did get involved in a study. Patients also said that the shock of their diagnosis made it hard to think about getting involved in research.

The authors of this study recommend that mesothelioma researchers offer different ways for patients and the public to get involved in research. One-time consultations could work well for people with difficult symptoms or a poor prognosis. Patients who are in better health might be interested in ongoing meetings or longer studies.

Source

Marcu A, McGregor F, Egan B, Hill K, Cook T, Arber A. Developing sustainable patient and public involvement in mesothelioma research: multi-method exploration with researchers, patients, carers, and patient organisations. Res Involv Engagem. 2023;9(1):15. Published 2023 Mar 25. doi:10.1186/s40900-023-00426-5. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10039679/

Similar Posts

  • |

    Ape Virus Shrinks Mesothelioma Tumors in Lab

    A virus that causes leukemia in gibbon apes may have the power to help fight malignant mesothelioma in people. Gibbon ape leukemia virus (GALV) has been tested for years as a viral vector, a carrier of therapeutic genetic information, in the treatment of various human illnesses, including cancer. A new study in Japan compared GALV with a leukemia virus derived from mice to see which carrier communicated most efficiently with mesothelioma cells. While both types of viruses replicated in most of the mesothelioma cell lines tested, the mouse-derived virus was not effective in a mesothelioma cell line called ACC-MESO-1. In this cell line, only the GALV spread efficiently both in culture and in mice that had been given human mesothelioma…

  • | |

    Micro-RNAs May Offer New Way to Fight Mesothelioma

    Scientists at one of the world’s top mesothelioma research centers, the Asbestos Diseases Research institute in Sydney, Australia, say that restoring the expression of certain micro RNAs in the cells of mesothelioma patients may offer a new way to fight the disease. A microRNA is a small RNA molecule which is involved in the regulation of gene expression. According to a new report in the Annals of Oncology, the Australian scientists found reduced expression of the micro RNA-15 family (miR-15/16) in the cells of mice with mesothelioma. “When malignant pleural mesothelioma cell lines were compared with the normal mesothelial cell line MeT-5A, the downregulation of miR-15/16 was 2- to 10-fold,” they report. This finding is consistent with previous cancer research…

  • |

    Mesothelioma Still Carries Heavy Mortality Burden in U.S.

    Asbestos exposure cost Americans more than 427,000 years of potential life in the first decade of the new millennium. That figure comes from a study on mesothelioma and asbestosis – the two most deadly asbestos-related diseases – conducted by the CDC’s National Institute for Occupational Safety and Health (NIOSH). Using National Center for Health Statistics mortality data, NIOSH researchers evaluated premature deaths and “loss of potentially productive years of life” attributable to either asbestosis or mesothelioma between 1999 and 2010. The data included only people 25 years or older with an underlying cause of death listed on their death certificate of either asbestosis or malignant mesothelioma. When the figures were calculated using the normal life expectancy for each asbestosis victim…

  • | |

    Treatment Uses Herpes Virus to Shrink Mesothelioma Tumors

    Researchers at a hospital in Sheffield, England are testing a potential new mesothelioma treatment based on the same virus that causes herpes. The small-scale trial is the first in the world to test the modified herpes simplex virus, HSV1716, in human mesothelioma patients. HSV1716 has been genetically engineered to infect and kill cancer cells without harming healthy cells. In laboratory studies on mesothelioma and some other cancers, it has been shown to be effective at shrinking tumors while causing limited toxicity. Just as significantly, HSV1716 increased survival rates among mice with various human cancers. The Phase I/II trial at Sheffield Experimental Cancer Medicine Centre is the next stage in development of HSV1716 as a viable mesothelioma treatment. The goal of…

  • | |

    New Mesothelioma Drug Kills Cancer Stem Cells

    Citing “significant enthusiasm within the mesothelioma community”, the manufacturers of a promising new mesothelioma drug say they have begun a major test of the drug in patients. Massachusetts-based Verastem, Inc. focuses on drugs that fight cancer by attacking the stem cells that give rise to them. Earlier this summer, the FDA granted orphan drug status to their stem cell inhibitor, defactinib, for the treatment of mesothelioma. The designation, which is reserved for drugs that fight the rarest of diseases, helps pave the way for testing and faster approval, depending on the results of clinical trials. “Development of a drug that preferentially kills cancer stem cells is a promising approach, as many standard-of-care treatments have been shown to either have no…

  • | |

    Mesothelioma Study Finds New Treatment Target

    Immunotherapy, which involves reprogramming T-cells to find and attack cancer cells, is one of the fastest-growing areas of cancer research. One of the biggest challenges of immunotherapy is how to harness the power of T-cells against cancer without also turning them against healthy cells. A new study conducted in Switzerland and published in the Journal of Translational Medicine addressed the problem by reprogramming T-cells to recognize and attack mesothelioma cells that express a specific protein. Fibroblast Activation Protein (FAP) is expressed on the surface of tumor-associated fibroblast cells which are found in the connective tissue of mesothelioma tumors. FAP is also found in mesothelioma cells and may play a role in the start of cancer, as well as the growth…